Arcadia Biosciences (RKDA) Current Deferred Revenue (2014 - 2021)

Arcadia Biosciences' Current Deferred Revenue history runs 8 years deep, the most recent figure standing at $63000.0 for Q2 2021.

• Quarterly Current Deferred Revenue changed N/A year-over-year to $63000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $63000.0 (changed N/A YoY) and the FY2020 annual result came in at $8000.0, down 80.95% from the prior year.
• Current Deferred Revenue was $63000.0 for Q2 2021 at Arcadia Biosciences, roughly flat from $63000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.0 million in Q4 2017 and bottomed at $8000.0 in Q4 2020.
• A 5-year average of $310875.0 and a median of $88000.0 in 2018 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2019 — Current Deferred Revenue slumped 96.81% — and 2021, when it jumped 270.59%.
• Arcadia Biosciences' Current Deferred Revenue stood at $1.0 million in 2017, then tumbled by 90.4% to $96000.0 in 2018, then sank by 56.25% to $42000.0 in 2019, then tumbled by 80.95% to $8000.0 in 2020, then surged by 687.5% to $63000.0 in 2021.
• Business Quant data shows RKDA's Current Deferred Revenue at $63000.0 in Q2 2021, $63000.0 in Q1 2021, and $8000.0 in Q4 2020.